Opinion|Videos|November 8, 2024
Personalizing Treatments and Patient Education
Key Takeaways
- Personalizing treatment regimens involves adjusting dosing schedules and administration routes to improve adherence and quality of life.
- Evaluating patient-specific factors, such as lifestyle and preferences, is crucial in developing personalized treatment plans.
Panelists discuss how treatment regimens for multiple myeloma patients can be personalized to improve adherence and quality of life by considering factors such as dosing schedules and routes of administration while emphasizing the role of pharmacists in providing resources and support to keep patients informed, engaged, and compliant with their individualized treatment plans.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How can a patient's treatment regimen be personalized to improve adherence and quality of life (eg, dosing schedule, route of administration), and how are those factors weighed or evaluated when developing treatment plans?
- (Dr Adams) What resources or support can pharmacists offer to keep patients informed, engaged, and compliant with their treatment plans?
Advertisement
Related to this article
Convenience should not replace connection.
Treated patients also had fewer post-acute hospitalizations and deaths, but individuals without risk factors saw no benefit.
A pharmacy technician reflects on 3 patient encounters that reshaped his
understanding of what a real patient requires.
In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg/d was linked to more kidney failure and higher all-cause mortality.
Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with the rare airway disease.
Caitlin McClain, a nurse and Clostridioides difficile infection (CDI) survivor, says pharmacists are well placed to help patients tell routine antibiotic adverse effects apart from CDI, which could lead to earlier diagnosis.
A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.
Before lung cancer therapy begins, diagnostic findings and treatment readiness shape care, creating opportunities for pharmacists to help patients start safely.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants Accelerated Approval to First Plasmid DNA-Based Immunotherapy for Recurrent Respiratory Papillomatosis
2
Diabetes Awareness Month Opens Amid New T1D, T2D Approvals
3
Community Pharmacists Guide Patients New to Glucose Monitoring
4
Very Low Protein Intake Tied to Higher Kidney Failure Risk in CKD
5